Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
David KirskeCFO | X4 PharmaceuticalsXFOR | Open-market sale | 05/12 | 05/13 | 16,961 sh | $4.29 | $72,762.69 | −8.8% |
Adam R. CraigExecutive Chairman | X4 PharmaceuticalsXFOR | Open-market buy | 25/10/23 | 25/10/27 | 86,206 sh | $2.90 | $249,997.4 | +29.7% |
Baldry MarkChief Commercial Officer | X4 PharmaceuticalsXFOR | Open-market buy | 25/05/16 | 25/05/20 | 1,032 sh | $2.48 | $2,559.36 | +4.2% |
X4 PharmaceuticalsXFOR | Open-market buy | 24/05/17–24/11/15 | 25/02/14 | 35,050 sh2 trades | $0.55avg. | $19,276.64 | +37.2% | |
Baldry MarkChief Commercial Officer | X4 PharmaceuticalsXFOR | Open-market sale | 25/01/24 | 25/01/27 | 29,159 sh | $0.45 | $13,121.55 | −23.7% |
X4 PharmaceuticalsXFOR | Open-market sale | 25/01/24 | 25/01/27 | 74,773 sh | $0.45 | $33,647.85 | −100.0% | |
Ragan PaulaPresident and CEO | X4 PharmaceuticalsXFOR | Open-market sale | 25/01/24 | 25/01/27 | 76,473 sh | $0.45 | $34,412.85 | −6.6% |
Arbet-Engels ChristopheChief Medical Officer | X4 PharmaceuticalsXFOR | Open-market sale | 25/01/24 | 25/01/27 | 11,624 sh | $0.45 | $5,230.8 | −45.0% |
DiBiase MaryCOO | X4 PharmaceuticalsXFOR | Open-market sale | 25/01/24 | 25/01/27 | 22,258 sh | $0.45 | $10,016.1 | −4.3% |
Ragan PaulaPresident and CEO | X4 PharmaceuticalsXFOR | Open-market sale | 24/11/15 | 24/11/19 | 31,897 sh | $0.39 | $12,439.83 | −3.1% |
Ragan PaulaPresident and CEO | X4 PharmaceuticalsXFOR | Open-market sale | 24/10/15 | 24/10/16 | 31,897 sh | $0.56 | $17,862.32 | −3.0% |
Baldry MarkChief Commercial Officer | X4 PharmaceuticalsXFOR | Open-market sale | 24/10/07 | 24/10/08 | 11,127 sh | $0.58 | $6,453.66 | −18.7% |
X4 PharmaceuticalsXFOR | Open-market sale | 24/10/07 | 24/10/08 | 230,645 sh | $0.55 | $126,854.75 | −100.0% | |
Ragan PaulaPresident and CEO | X4 PharmaceuticalsXFOR | Open-market sale | 24/10/07 | 24/10/08 | 239,436 sh | $0.55 | $131,689.8 | −18.5% |
Taveras ArthurChief Scientific Officer | X4 PharmaceuticalsXFOR | Open-market sale | 24/10/07 | 24/10/08 | 76,920 sh | $0.56 | $43,075.2 | −16.5% |
DiBiase MaryCOO | X4 PharmaceuticalsXFOR | Open-market sale | 24/10/07 | 24/10/08 | 67,695 sh | $0.57 | $38,586.15 | −13.0% |
DiBiase MaryCOO | X4 PharmaceuticalsXFOR | Open-market sale | 24/09/09 | 24/09/11 | 2,642 sh | $0.66 | $1,743.72 | −0.9% |
X4 PharmaceuticalsXFOR | Open-market sale | 24/03/11 | 24/03/11 | 52,500 sh | $0.88 | $46,200 | −100.0% | |
Ragan PaulaPresident and CEO | X4 PharmaceuticalsXFOR | Open-market sale | 24/03/11 | 24/03/11 | 49,678 sh | $0.88 | $43,716.64 | −6.1% |
Taveras ArthurChief Scientific Officer | X4 PharmaceuticalsXFOR | Open-market sale | 24/03/11 | 24/03/11 | 14,235 sh | $0.88 | $12,526.8 | −5.7% |